Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118332 · ClinicalTrials.gov registry record · Early Phase 1
Psilocybin as a Treatment for Chronic Pain in Smokers
A Early Phase 1 study, sponsored by Yale University.
- Not yet
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
NCT07118332 is a Early Phase 1 study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 10 participants.
The verdict
NCT07118332, a Early Phase 1 study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to understand whether psilocybin therapy is safe and well tolerated in improving chronic pain and increasing motivation to quit smoking for people who have chronic pain and smoke cigarettes. Psilocybin is a psychedelic drug and the active ingredient in "magic mushrooms." Psilocybin is currently being studied in clinical trials but has no current medical use in the United States. Some studies have shown that a dose of psilocybin can help people quit smoking. Other studies have shown that a dose of psilocybin may improve certain chronic pain conditions, such as migraine headaches. We believe that it may also be helpful for people who smoke and have chronic pain, but this has not been tested yet.
Interventions
- DRUG Psilocybin (drug)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-12-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07118332
The ClinicalTrials.gov registry entry for NCT07118332 describes a study currently listed as not yet recruiting, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin (drug) is the first listed.
NCT07118332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07118332 about?
NCT07118332 is a clinical study titled "Psilocybin as a Treatment for Chronic Pain in Smokers". The purpose of this study is to understand whether psilocybin therapy is safe and well tolerated in improving chronic pain and increasing motivation to quit smoking for people who have chronic pain and smoke cigarettes. Psilocybin is a psychedelic drug and the active ingredient in "magic mushrooms."...
What is the current status of trial NCT07118332?
This trial is currently not yet recruiting. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2026-07. Estimated completion is 2027-12-01.
What interventions are being tested in trial NCT07118332?
The interventions under investigation include: Psilocybin (drug) (DRUG).
Who is sponsoring clinical trial NCT07118332?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.